BridgeBio Pharma

BRIDGEBIO PHARMA INC

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

biotech shutter

Asia

Biotech

Large Cap

News

Health Care

Movers

Trading Ideas

General

BBIO

BridgeBio&#39;s acoramidis wins Japan&#39;s approval for ATTR-CM. Phase 3 data show a 42% reduction in key heart-related events. AstraZeneca&#39;s Alexion to market it.

Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug

Bernie's Concerns With Healthcare Costs

Short Ideas

Pre-Market Outlook

Markets

ISRG

ITCI

Top 4 Health Care Stocks You May Want To Dump In Q1

How Spot Gold Prices Reacted

Equities

Eurozone

Commodities

Intraday Update

CMAX

ONCT

QUBT

RGTI

SAVA

Gold Down Over 3%; Rigetti Computing Shares Spike Higher

BridgeBio Pharma Inc

Press Releases

BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt

Financing

BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt

BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting Medicines

Deep Track Capital Sends Letter to Dynavax Technologies' Board of Directors

Management

BridgeBio Announces CFO Succession

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions

Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM

Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM

BBOT Announces First Patient Dosed with BBO-11818, a PanKRAS Dual Inhibitor, in the Phase 1 KONQUER-101 Trial for Advanced Solid Tumors

DVAX

HLXB

ADMA Biologics

Alkermes

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Genmab

Grifols, S.A. - American Depositary Shares

Grifols

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Incyte

Insmed

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Krystal Biotech

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Nuvalent

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

TG Therapeutics

Telix Pharmaceuticals Limited - American Depositary Shares

Telix Pharmaceuticals

Redburn Atlantic

JP Morgan

Citigroup

Cantor Fitzgerald

Scotiabank

Comments

BridgeBio Pharma

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga